Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D’s Effect On Generic Statins; More ASHE In Brief

Executive Summary

Statins are primary Part D generic casualty: The Medicare Part D prescription drug benefit had negligible impact on generic utilization rates, according to a preliminary analysis of Walgreens claim data by James Zhang, Virginia Commonwealth University, and colleagues. In a June 23 presentation at the American Society of Health Economists meeting in Durham, N.C., Zhang reports that the odds ratio of generic utilization for Medicare eligible patients, defined as subjects ages 67-73 in 2006, relative to non-Medicare seniors, subjects ages 61-63, was .98. Authors estimate that potential costs to Medicare due to foregone generic substitutions were $2.1 billion in 2006. Antihyperlipidemics is the only drug class with statistically higher generic utilization for the Medicare-eligible population, the authors report. Merck's blockbuster cholesterol agent Zocor (simvastatin) was a primary focus of insurer generic substitution efforts when the statin lost market exclusivity in June 2006, the first year of the drug benefit (1"The Pink Sheet," July 30, 2007, p. 16). In a separate presentation at ASHE, IMS Health Senior VP-Corporate Strategy Murray Aitken reports that generics account for the same percentage of scripts inside and outside of Part D
Advertisement

Related Content

Biologics Exclusivity Will Be Less Then 10 Years, Teva’s Marth Vows
Biologics Exclusivity Will Be Less Then 10 Years, Teva’s Marth Vows
Biogeneric Exclusivity Debate: At Least 14 Years Or “Hard And Fast” Combo?
Medicare Part D Boosts Public Share Of Retail Drug Spending To 34 Percent
Generic Simvastatin No Heartache For Crestor Or Vytorin
Generic Simvastatin No Heartache For Crestor Or Vytorin
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
Advertisement
UsernamePublicRestriction

Register

PS049820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel